OncoSec to Present at Scientific and Investment Conferences in September

SAN DIEGO, Sept. 2, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in September, including:

- First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies; Portorož, Slovenia
- Rodman & Renshaw 17th Annual Global Investment Conference; New York, NY
- Second Annual Global Summit on Practical and Emerging Trends in Melanoma; Pasadena, CA
- European Cancer Congress 2015; Vienna, Austria
- Sachs 15th Annual Biotech in Europe Forum; Basel, Switzerland

First World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Robert H. Pierce, MD, Chief Scientific Officer, will present a keynote lecture entitled: "Advances in Clinical Electroporation: Tissue Sensing, Feedback Control, and Catheter Technology" at the First World Congress on Electroporation and Pulsed Electric Fields on September 9 at 4:30 PM CEST at the Grand Hotel Bernardin in Portorož, Slovenia. OncoSec will also be presenting a poster entitled: "Development of a Catheter-Based Applicator for Immuno-Oncology."

Richard Heller, PhD, member of OncoSec's Scientific Advisory Board and Professor at the School of Medical Diagnostics and Translational Sciences at Old Dominion University, will present a lecture during the "Medical Applications: Gene Therapy" session on September 9 entitled: "Effective Enhancement of Immune Response Utilizing Gene Electro-Transfer."

Adil Daud, MD, member of OncoSec's Melanoma Advisory Board and Professor of Medicine at the University of California, San Francisco, will also present a lecture on September 9 entitled: "Clinical Trials with Plasmid IL-12 Electroporation in Melanoma and Merkel Cell Cancer."

This meeting brings together individuals possessing diverse expertise, who are involved in basic research or are developing applications based on electroporation and the use of pulsed electric fields of high intensity. The aim is to create a stimulating interdisciplinary environment to present the latest achievements and demonstrate current knowledge in this rapidly advancing field. For more information, please visit: https://wc2015.electroporation.net.

Rodman & Renshaw 17th Annual Global Investment Conference
Punit Dhillon, President and CEO, will present a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference on September 9 at 10:00 AM ET at the St. Regis Hotel in New York City. To view and listen to the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/rrshq25/oncs. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.

This conference brings together growth companies and a vast audience of financial and strategic investors for in-depth corporate presentations, as well as to facilitate one-on-one investor and networking meetings. For more information, please visit: http://www.rodm.com.

Second Annual Global Summit on Practical and Emerging Trends in Melanoma
Dr. Pierce will present a lecture entitled: "Reversing Immune Tolerance through Intratumoral Gene Electrotransfer" during the "Emerging Technologies" session at the Second Annual Global Summit on Practical and Emerging Trends in Melanoma on September 19 starting at 11:15 AM PT at The Langham Hotel in Pasadena, CA.

The focus of this summit is to translate the most recent research and insights into patient care. Leaders will discuss the evolution of the standard care in melanoma; advancing the care of melanoma; integration of immune checkpoint inhibitors into the treatment of melanoma; and new targets in melanoma. For more information, please visit: http://www.omionc.com/melanoma2015.
European Cancer Congress 2015
Shailender Bhatia, MD, from the University of Washington School of Medicine and principal investigator for OncoSec's Phase II Merkel cell carcinoma trial, will present final results from this study in an oral presentation entitled: "Intratumoral Delivery of Interleukin-12 DNA via In Vivo Electroporation Leads to Regression of Injected and Non-injected Tumors in Merkel Cell Carcinoma: Final Results of a Phase II Study" at the European Cancer Congress on September 27 at 6:15 PM CEST at the Messe Wien Exhibition & Congress Centre in Vienna, Austria.

The European Cancer Congress (ECC2015) is a biennial meeting, which combines the efforts of oncology professionals with the aim of improving the prevention, diagnosis, treatment, and care of cancer patients. It is the largest European platform for presenting groundbreaking data to a global audience and the ideal environment for participants to leverage knowledge, promote education, and build awareness about oncology. For more information, please visit: http://www.europeancancercongress.org/.

Sachs 15th Annual Biotech in Europe Forum
Punit Dhillon, President and CEO, will present a corporate overview at the Sachs 15th Annual Biotech in Europe Forum on September 30 at 11:30 AM CEST at the Congress Center Basel in Basel, Switzerland. Mr. Dhillon will also participate in an "Oncology III – Pharma/Biotech BD&L" panel on September 30 at 2:00 PM CEST.

The forum provides an international stage for those interested in investing and partnering in the biotech and life science industry. The forum draws together a cross-section of early-stage, late-stage and public companies with leading investors, analysts, money managers and pharmaceutical licensing executives. Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, this event will garner over 700+ delegates and 120+ presenting companies. For more information, please visit: http://www.sachsforum.com/.

About OncoSec Medical Incorporated
OncoSec is a biopharmaceutical company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck (HNSCC), and triple-negative breast cancer (TNBC). In addition to ImmunoPulse™ IL-12, the company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com

Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
To view the original version on PR Newswire, visit:

SOURCE OncoSec Medical Incorporated